Skip to Main text

  • LinkedIn
  • mail
  • copy
    Link copied
  • Company News

Manufacturing Capacity Expansion for Oligonucleotide Active Pharmaceutical Ingredients in US

Nitto Denko Avecia Inc. (Headquarters: Massachusetts, USA, President: Detlef Rethage, referred to hereafter as “Avecia”), a subsidiary of Nitto Denko Corporation (Headquarters: Osaka, CEO: Hideo Takasaki, referred to hereafter as “Nitto”) has established the new facility in its manufacturing plant in Milford, Massachusetts, in order to expand manufacturing capacity for oligonucleotide active pharmaceutical ingredients (API). Its manufacturing capacity has increased from 1.2 mol to 3.0 mol, making Avecia the largest oligonucleotide manufacturing site in the world.


Nitto acquired Avecia in 2011 to offer value in the field of oligonucleotide therapeutics and since the acquisition, the oligonucleotide manufacturing services it provides to its customers have boasted top global market share. In October 2016, Nitto also acquired the assets of Irvine Pharmaceutical Services, a leading analytical development services provider, and Avrio Biopharmaceuticals, a pharmaceutical company offering aseptic fill & finish services, in order to further expand its services.
Recently, Avecia has expanded the manufacturing and office space at its Milford facility by 20,000 square feet, adding equipment with a maximum oligonucleotide API manufacturing capacity of 1.8 mol, bringing the total manufacturing capacity to 3.0 mol and thereby strengthening Avecia’s position as the largest oligonucleotide manufacturing site in the world.
There will be a ribbon cutting ceremony to mark the opening of the expanded facility on August 2nd.

Commenting on the increase in manufacturing capacity, Avecia’s president Detlef Rethage stated, “This expansion will help Avecia’s clients to receive timely oligonucleotide API to advance their drug development programs in clinical trials as planned. Avecia takes pride that our engineers have introduced novel technology and executed this expansion in record time, all in close collaboration with A/Z Corporation to ensure the timely supply of novel oligonucleotide therapeutics.”

Under the brand slogan “Innovation for Customers”, Nitto is expanding its business reach in the fields of Green (Environment), Clean (New Energy) and Fine (Life Sciences), in order to contribute to its customer’s value creation. Nitto will use this increased manufacturing capacity in the “Fine” (Life Sciences) field to provide services that further advance its customers’ development of oligonucleotide therapeutics.

What are oligonucleotide therapeutics?

Oligonucleotide therapeutics are comprised of nucleic acids such as DNA and RNA. Along with antibody drugs, they have great future potential as a next-generation pharmaceutical product. Due to their direct effect on gene expression, oligonucleotide drugs may prove to be a revolutionary medicine that enables the treatment of illnesses that have previously been difficult to treat and commercial development is quickly gaining momentum.

About Nitto Denko Avecia Inc.

Nitto Denko Avecia Inc. is a recognized leader in manufacturing and development services of oligonucleotide therapeutics, with facilities located in Milford, MA.; Marlboro, MA.; and Cincinnati OH offering services for DNA, RNA and other oligonucleotides based therapeutics from milligram scale at pre-clinical stage to 1000 kg + post commercial launch. More

About Nitto Avecia Pharma Services Inc.

Nitto Avecia Pharma Services is your single solution for premier contract development and manufacturing services. Nitto Avecia Pharma Services supports the pharmaceutical, biopharmaceutical, and medical device industries with a complete package of cGMP services including pre-formulation/formulation, parenteral manufacturing, analytical development, biopharmaceutical development, structural chemistry, analytical chemistry, microbiology, stability storage and drug delivery device testing. With three state-of-the-art facilities located on one campus in Irvine, CA. Learn more at
* cGMP is an abbreviation for Current Good Manufacturing Practice. cGMP refers to the US Food and Drug Administration quality management system used in the manufacturing and testing of pharmaceuticals and other such products.

Contact Us

For any inquiries about this press release.

Business Hours (EST)
8:00 a.m.-5:30 p.m.(Except for Sat, Sun, and Holidays)

  • LinkedIn
  • mail
  • copy
Here is the information at the release day. This information may be different from the information at other medias. Please be forewarned.